# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
– License of proprietary masking platform further strengthens Vir's drug discovery capabilities in oncology and infectious ...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $110 pri...
Barclays analyst Gena Wang maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $27 t...
Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(1.02) per share which missed the analyst consensus estimate of $(...